论文部分内容阅读
目的:对武汉地区2012~2014年保肝药物临床应用情况进行分析,为临床合理用药和科学管理提供参考。方法:采用世界卫生组织推荐的限定日剂量为指标的分析方法,对武汉地区2012~2014年34家样本医院保肝药总销售金额、用药频度(DDDs)、限定日费用(DDC)、排序比等进行回顾性统计分析。结果:武汉地区2012~2014年保肝药总体销售金额和用药频度逐年升高,排序前10位的品种变化不大。每年均以异甘草酸镁销售金额最高,其次是鸟氨酸-门冬氨酸,核糖核酸,甘草甜素、半胱氨酸疏基丙氨酸复方制剂和多烯磷脂酰胆碱。2012~2013年用药频度居于前2位的是甘草甜素、半胱氨酸疏基丙氨酸复方制剂和水飞蓟素,2014年是促肝细胞生长素和苦参素。3年来,金额排名前30位的药品中,每年均有7个品种排序比小于0.5。结论:武汉地区保肝药的市场前景广阔,临床应用基本合理,但仍存在个别品种应用不合理的情况。
Objective: To analyze the clinical application of hepatoprotective drugs from 2012 to 2014 in Wuhan, and to provide reference for clinical rational drug use and scientific management. Methods: According to the recommended daily limit of dosage recommended by the World Health Organization (WHO), the total sales amount, frequency of DDDs, DDC of 34 samples of hospitals in Wuhan in 2012 ~ 2014 were sorted. Than the retrospective statistical analysis. Results: The total sales amount and medication frequency of hepatoprotective drugs in Wuhan from 2012 to 2014 increased year by year, with no significant change in the top 10 varieties. Every year, the sales amount of isoglycyrrhizinate is the highest, followed by ornithine-aspartic acid, ribonucleic acid, glycyrrhizin, cysteinyl-lysyl-alanine compound and polyene phosphatidylcholine. The frequency of medication in 2012-2013 was in the top two places of glycyrrhizin, cysteamine and alanine compound preparations and silymarin, 2014 is the promotion of hepatocyte growth hormone and oxymatrine. In the past three years, out of the top 30 drugs in the amount, seven varieties ranked less than 0.5 each year. Conclusion: The market of hepatoprotective drugs in Wuhan is broad and its clinical application is basically reasonable. However, there are still some unreasonable application of some varieties.